Announced
Completed
Financials
Sources
Tags
Completed
Acquisition
pharmaceutical
Single Bidder
Pharmaceuticals
Domestic
Private
Private Equity
Friendly
Majority
United States
life sciences
Synopsis
ArchiMed-backed NAMSA, a provider of full continuum development solutions, completed its acquisition of Syntactx, a CRO with expertise in complex interventional medical device and pharmaceutical trials across multiple therapeutic areas. Financial terms were not disclosed. "Not only are our values and cultures well-aligned, but both organizations have a strong commitment to enhancing patient healthcare by safely and judiciously helping clients deliver innovative, life-changing medical devices to the global marketplace," John Gorski, NAMSA President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.